Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

TD Cowen initiated coverage of Avalo Therapeutics with a rating of Buy

Cantor Fitzgerald initiated coverage of Avalo Therapeutics with a rating of Overweight

H.C. Wainwright resumed coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $15.00

Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the "Option"). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Option was granted on May 21, 2026 and has an exercise price of $16.60 per share, which is e

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Avalo. In addition, Avalo intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its com

Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest rates observed in a trial of this size or largerStatistically significant benefit was demonstrated on key secondary endpoints of HiSCR50, change in IHS4 and change in draining tunnel countAbdakibart was well tolerated with a favorable safety profile Avalo plans to advance abdakibart into a registrational phase 3 program WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β based treat

WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement (the "Buyout Agreement") related to the company's prior acquisition of AlmataBio, Inc. in March of 2024. Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combinatio

Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026Cash, cash equivalents and short-term investments of approximately $98 million as of December 31, 2025 expected to provide runway into 2028 WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025. "2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approac

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: TD Cowen Annual Healthcare ConferenceFireside Chat March 3, 2026, at 9:50 am ET Leerink Partners Global Healthcare ConferenceFireside ChatMarch 10, 2026, at 4:20 pm ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for

WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the "Options") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted on February 13, 2026 and have an exercise price of $14.

WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 10:00 am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast

SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

10-Q - Avalo Therapeutics, Inc. (0001534120) (Filer)

8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)

8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

-       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. "We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Phase 2 LOTUS Trial in patients with hidradenitis suppurativa. Mittie brings to Avalo a strong combination of drug development experience through all stages of development and exceptional expertise in immunology, rheumatology and dermatology," said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. "Her leadership guided by her robust experience will be invaluable to th

WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. "We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement earlier this year," said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. "Paul's deep industry experience will immediately enhance our strategic and legal competencies. Furthermore, we expect his appointment will augment our ability to create and protect value as well as minimize risk as we progress AVTX-009 in hidradenitis suppurativa and plan for the

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)